STAT+: BridgeBio drug for genetic cause of dwarfism succeeds in key study
STAT [Unofficial]
February 12, 2026
BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal clinical trial.
Discussion in the ATmosphere